BRIEF: WTVG-TV names new general manager

The Blade |

--Chris Fedele has been named the new General Manager of WTVG-TV, Channel 13 in Toledo, it was announced by station owner Gray Television Inc. in Atlanta.

A native of northeast Indiana, Mr. Fedele has worked 25 years for Gray Television Inc. He replaces WTVG General Manager Pete Veto, who is leaving to focus on his hometown station WJRT-ABC in Flint, Mich.

Mr. Fedele returns after a decade as director of sales and marketing for WLEX-TV in Lexington, Ky. Before that, he was president and general manager of WPTA-TV in Fort Wayne, Ind. He also spent 14 years as the general sales manager, local sales manager, and national sales manager at various times at WPTA-TV.

Gray Television did not return calls about when he will assume his Toledo duties.

Guidelines: Please keep your comments smart and civil. Don't attack other readers personally, and keep your language decent. Comments that violate these standards, or our privacy statement or visitor's agreement, are subject to being removed and commenters are subject to being banned. To post comments, you must be a registered user on toledoblade.com. To find out more, please visit the FAQ.

___

(c)2018 The Blade (Toledo, Ohio)

Visit The Blade (Toledo, Ohio) at www.toledoblade.com

Distributed by Tribune Content Agency, LLC.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

Level Headed at World Crypto Con - Steve Beauregard

Bloq.com CRO Steve Beauregard joins Jack Brewer at World Crypto Con.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.